Brief: Cocrystal Pharma Receives FDA Guidance To Advance Clinical Development Of Its COVID-19 Antiviral CDI-45205

Cocrystal Pharma

06/01/2022 13:24

Jan 6 (Reuters) - Cocrystal Pharma Inc  COCP.O :
    * COCRYSTAL PHARMA RECEIVES FDA GUIDANCE TO ADVANCE CLINICAL
DEVELOPMENT OF ITS COVID-19 ANTIVIRAL CDI-45205
    * RESPONSE TO PRE-IND BRIEFING PACKAGE SUPPORTS PATHWAY TO
INITIATING A PHASE 1 CLINICAL STUDY IN 2022
    * COCRYSTAL PHARMA - HAVE CLEARER PATHWAY FOR PLANNED PHASE
1
SINGLE-ASCENDING-DOSE & MULTIPLE-ASCENDING-DOSE STUDY THAT CO
EXPECTS TO INITIATE IN 2022
    * INTENDS TO CONDUCT CDI-45205 FORMULATION DEVELOPMENT,
IND-ENABLING STUDIES AND VIROLOGY ASSESSMENTS
    * IN SECOND COVID-19 PROGRAM, PLANS TO BEGIN A PHASE 1 STUDY
ALSO
IN 2022 WITH AN ORALLY ADMINISTERED MAIN PROTEASE INHIBITOR

Source text for Eikon:  ID:nGNX3T7MbW 
Further company coverage:  COCP.O 

 ((Reuters.Briefs@thomsonreuters.com;))